A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 34
- Population
- ALL · 50 Years
- Duration
- 2021-04-13 to 2021-09-22
- Intervention
- Data extraction from medical files
- Comparator
- Not reported
- Outcomes measured
- Injections number (first 24 months of treatment) — first 24 months of treatment; Injections interval — during the 2nd year of treatment; Injection number (up to 4 years of treatment) — up to 4 years of treatment; Injections interval (up to 4 years of treatment) — up to 4 years of treatment; Most stable injection interval — up to 4 years of treatment; Overall extension interval — up to 4 years of treatment; Covid 19 impact — up to 4 years of treatment; Number of follow-up visits — up to 4 years of treatment; Visual acuity — up to 4 years of treatment; Age — Baseline; Eye lesion type — Baseline; Fluid — Baseline; Fluid — 90 days after baseline; Fluid — once a year up to 4 years of treatment; Date of first symptoms — Baseline; Date of first injection — Baseline; Retinal thickness — up to 4 years of treatment; Treatment regimen — first 12 months of treatment]; Number of patients stopping treatment (12-24 months) — between 12 and 24 months of treatment; Reason for stopping treatment (12-24 months) — between 12 and 24 months of treatment
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.